Drug Trial Radar · NCT06608134
Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Oct 1, 2028
Study completion Oct 1, 2029
Sponsor
- Lead sponsor
- R3 Medical ResearchIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.
Conditions
- Osteoarthritis, Knee
Interventions
Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee InjectionBiological
Direct injection of biologic into the knee joint.
Primary outcomes
What the sponsor says the trial is designed to measure.
- C Reactive ProteinTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
- Erythrocyte Sedimentation RateTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
- Alanine TransaminaseTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
- Aspartate TransaminaseTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
- Alkaline PhosphataseTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
- AlbuminTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
- CreatinineTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
- Blood Urea NitrogenTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
R3 Anti Aging Scottsdale
Scottsdale, Arizona · Recruiting
R3 Anti Aging Beverly Hills
Beverly Hills, California · Recruiting
Optimal Medical Group
Fresno, California · Recruiting
Scheer Medical Wellness
New York, New York · Recruiting
Dr. Duc (Steve) Le, MD
Cleveland, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.